Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects
试验速览
- 阶段
- 不适用
- 入组人数
- 96
- 试验地点
- 2
- 主要终点
- Resting Metabolic Rate
研究概览
简要总结
The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 22 Years 至 52 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 22-52 years Body mass index equal or more than 30
排除标准
- •Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug
研究组 & 干预措施
Vitamin D analogue
1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
干预措施: Vitamin D analogue (Dietary Supplement)
Placebo
Corn oil pearl Capsules 1 gram
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Resting Metabolic Rate
时间窗: Change from baseline to 8 weeks
Measurement by indirect calorimetry.
次要结局
- Changes of Nesfatin-1, PPARγ and PGC1α protein levels(Change from baseline to 8 weeks)
